This study reveals the critical role of PFKFB3 in glucose metabolism disorder following AP and is the first to apply cell membrane nanovesicle technology to deliver the PFKFB3 small molecule inhibitor quercetin. The gene discussed is PFKFB3; the disease is alkaline phosphatase measurement.